ArticleMicroscopy research and technique2026
Dose-Dependent Protective Effects of Agmatine on Sublingual Gland Dysfunction and Pancreatic Damage in Experimental Diabetes: Evidence From Histological, Biochemical, and Immunohistochemical Analyses.
Article in Microscopy research and technique, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) induces endocrine and exocrine dysfunction, including salivary gland impairment. While the sublingual gland (SLG) contributes to saliva production, its involvement in diabetes remains understudied. Agmatine (AGM), a naturally occurring polyamine, exhibits antioxidant and anti-inflammatory properties; however, its protective effects on the SLG and pancreas in diabetes have remained largely uninvestigated. This study introduces new insights into SLG injury in diabetes and the dose-dependent protective benefits of AGM through multi-level analysis. Male Wistar rats were rendered diabetic by a single intraperitoneal STZ injection (65 mg/kg) and treated with either low-dose (40 mg/kg) or high-dose (100 mg/kg) AGM for two weeks. SLGs and the pancreas were analyzed by histological, immunohistochemical, and biochemical methods. Mucin secretion (MUC-5B) was measured, oxidative stress markers and pro-inflammatory cytokines were quantified, and structural changes were evaluated using H&E, Alcian Blue/PAS, and Mallory's trichrome staining. Immunohistochemistry included α-SMA and CK17 for SLG and insulin receptor for the pancreas. STZ-induced diabetes resulted in a substantial reduction in MUC-5B, increased oxidative stress and pro-inflammatory markers, damage to acinar and myoepithelial cells, and injury to pancreatic β-cells. Agmatine administration enhanced these parameters in a dose-dependent manner, with high-dose treatment reinstating mucin secretion, regulating oxidative and inflammatory indicators, and maintaining histological and immunohistochemical integrity in both the sublingual gland and pancreas. AGM confers dose-dependent protection against SLG dysfunction and pancreatic damage in diabetic rats via antioxidant, anti-inflammatory, and cytoprotective mechanisms. These findings highlight the therapeutic potential of AGM in preventing salivary gland dysfunction and maintaining pancreatic function in diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.